{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T22:54:21Z","timestamp":1793141661252,"version":"4.5.0"},"reference-count":34,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T00:00:00Z","timestamp":1772496000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Kidney Paired Donation (KPD) programs expand transplant opportunities for immunologically incompatible donor-recipient pairs. This study describes the operational framework and clinical outcomes of a high-volume, single-center KPD program, which became the highest-volume center globally in 2024.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We analyzed all kidney transplants performed through our KPD program between January and December 2024. The program aimed to achieve full HLA and ABO compatibility for incompatible pairs, while also incorporating additional strategies: inclusion of compatible pairs to improve HLA matching, acceptance of ABO quasi-compatible matches (e.g., A2 donors to O or B recipients), low-risk HLA-incompatible matching for HLA-incompatible candidates with cPRA &amp;gt;80%, and ABO-incompatible matching for those with cPRA &amp;gt;95%.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 135 patients (121 adults, 14 pediatrics) underwent KPD-facilitated transplantation, including 69 HLA-incompatible (51.1%), 37 ABO-incompatible (27.4%), and 29 compatible (21.5%) pairs. Females comprised 60.7% of the cohort, with a significantly higher proportion in the HLA-incompatible group (p &amp;lt; 0.001). HLA-incompatible recipients were older than others (mean age 42.5 years, p &amp;lt; 0.001). Most transplants (93.3%) occurred through 2- to 5-way closed chains, with the remainder via domino chains (6.7%). At baseline, 25% of patients were very highly sensitized (cPRA \u226595%) HLA- incompatible recipients, and ABO-incompatible recipients were blood group O individuals whose intended donors had A1 or B blood groups (high risk combinations). Following matching, 70% of patients achieved full HLA and ABO compatibility, while 30% underwent transplantation with acceptable immunologic risk (i.e. low-risk HLA incompatibility and\/or ABO incompatibility). Early post-transplant outcomes were favorable, with a mean serum creatinine of 87.2 \u00b5mol\/L. Acute rejection occurred in 6.7% of patients, antibody-mediated rejection in 0.7%, and graft loss in 0.7%.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our single-center experience demonstrates the feasibility and effectiveness of a high-volume KPD program in overcoming immunologic barriers to kidney transplantation. Strategic inclusion of compatible pairs, ABO quasi-compatible matching, low-risk HLA-incompatible, and ABO-incompatible matchings significantly increased access for difficult-to-match recipients. This model may serve as a replicable framework for other high-capacity transplant centers seeking to expand transplant access and improve outcomes for complex patient populations.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1623684","type":"journal-article","created":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T05:23:09Z","timestamp":1772515389000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Innovative strategies in kidney paired donation: single-center experience achieving the highest annual transplant volume globally"],"prefix":"10.3389","volume":"17","author":[{"given":"Khalid A.","family":"AlMeshari","sequence":"first","affiliation":[{"name":"Department of Kidney and Pancreas Transplantation, King Faisal Specialist Hospital and Research Centre","place":["Riyadh, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dieter C.","family":"Broering","sequence":"additional","affiliation":[{"name":"Department of Kidney and Pancreas Transplantation, King Faisal Specialist Hospital and Research Centre","place":["Riyadh, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dalia A.","family":"Obeid","sequence":"additional","affiliation":[{"name":"Transplant Research and Innovation Department, Organ Transplant Centre of Excellence, King Faisal Specialist Hospital and Research Centre","place":["Riyadh, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali N.","family":"AlAli","sequence":"additional","affiliation":[{"name":"Department of Kidney and Pancreas Transplantation, King Faisal Specialist Hospital and Research Centre","place":["Riyadh, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amal N.","family":"Algharabli","sequence":"additional","affiliation":[{"name":"Department of Kidney and Pancreas Transplantation, King Faisal Specialist Hospital and Research Centre","place":["Riyadh, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noreen L.","family":"Pana","sequence":"additional","affiliation":[{"name":"Department of Kidney and Pancreas Transplantation, King Faisal Specialist Hospital and Research Centre","place":["Riyadh, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tariq Z.","family":"Ali","sequence":"additional","affiliation":[{"name":"Department of Kidney and Pancreas Transplantation, King Faisal Specialist Hospital and Research Centre","place":["Riyadh, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,3,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2011.03686.x","article-title":"Systematic review: Kidney transplantation compared with dialysis in clinically relevant outcomes","volume":"11","author":"Tonelli","year":"2011","journal-title":"Am J Transplant"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199912023412303","article-title":"Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant","volume":"341","author":"Wolfe","year":"1999","journal-title":"N Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.ejim.2024.11.010","article-title":"Transforming organ donation and transplantation: Strategies for increasing donor participation and system efficiency","volume":"133","author":"Olawade","year":"2025","journal-title":"Eur J Intern Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1007\/s00467-014-2868-6","article-title":"HLA sensitisation: Can it be prevented","volume":"30","author":"Rees","year":"2015","journal-title":"Pediatr Nephrol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.trim.2013.05.001","article-title":"Pre-transplant donor specific anti-HLA antibody is associated with antibody-mediated rejection, progressive graft dysfunction and patient death","volume":"28","author":"Fidler","year":"2013","journal-title":"Transpl Immunol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.humimm.2017.05.007","article-title":"Understanding solid-phase HLA antibody assays and the value of MFI","volume":"78","author":"Sullivan","year":"2017","journal-title":"Hum Immunol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.13168","article-title":"Positive crossmatch kidney transplant recipients treated with eculizumab: Outcomes beyond 1 year","volume":"15","author":"Cornell","year":"2015","journal-title":"Am J Transplant"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.11641115","article-title":"HLA-DQ mismatches and rejection in kidney transplant recipients","volume":"11","author":"Lim","year":"2016","journal-title":"Clin J Am Soc Nephrol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2021.06.026","article-title":"Significance of HLA-DQ in kidney transplantation: Time to reevaluate human leukocyte antigen-matching priorities to improve transplant outcomes? an expert review and recommendations","volume":"100","author":"Tambur","year":"2021","journal-title":"Kidney Int"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.10860917","article-title":"HLA-DQ mismatching and kidney transplant outcomes","volume":"13","author":"Leeaphorn","year":"2018","journal-title":"Clin J Am Soc Nephrol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2016.00469","article-title":"Reflections on HLA epitope-based matching for transplantation","volume":"7","author":"Duquesnoy","year":"2016","journal-title":"Front Immunol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1097\/MOT.0000000000000539","article-title":"Epitope-based human leukocyte antigen matching for transplantation: A personal perspective of its future","volume":"23","author":"Duquesnoy","year":"2018","journal-title":"Curr Opin Organ Transplant"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1097\/MOT.0000000000000657","article-title":"Epitope matching in kidney transplantation: Recent advances and current limitations","volume":"24","author":"Larkins","year":"2019","journal-title":"Curr Opin Organ Transplant"},{"key":"B14","doi-asserted-by":"publisher","first-page":"59","DOI":"10.6002\/ect.DonorSymp.2022.O2","article-title":"Kidney paired donation","volume":"20","author":"Hassaballa","year":"2022","journal-title":"Exp Clin Transplant"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1001\/jama.293.15.1883","article-title":"Kidney paired donation and optimizing the use of live donor organs","volume":"293","author":"Segev","year":"2005","journal-title":"JAMA"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2007.01935.x","article-title":"Expanding kidney paired donation through participation by compatible pairs","volume":"7","author":"Gentry","year":"2007","journal-title":"Am J Transplant"},{"key":"B17","unstructured":"2025"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2005.01024.x","article-title":"The dutch national living donor kidney exchange program","volume":"5","author":"Marry","year":"2005","journal-title":"Am J Transplant"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1186\/2054-3581-1-6","article-title":"Foundations and principles of the canadian living donor paired exchange program","volume":"1","author":"Malik","year":"2014","journal-title":"Can J Kidney Health Dis"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1996","DOI":"10.1097\/TP.0000000000001778","article-title":"Kidney paired donation and the \u201cvaluable consideration\u201d problem: The experiences of Australia, Canada, and the United States","volume":"101","author":"Toews","year":"2017","journal-title":"Transplantation"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1111\/nep.12369","article-title":"Four years of experience with the Australian kidney paired donation programme","volume":"20","author":"Cantwell","year":"2015","journal-title":"Nephrol (Carlton)"},{"key":"B22","unstructured":"Kidney Match for Life\n          \n          2025"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.13709","article-title":"A risk index for living donor kidney transplantation","volume":"16","author":"Massie","year":"2016","journal-title":"Am J Transplant"},{"key":"B24","doi-asserted-by":"crossref","unstructured":"National Kidney Registry\n          \n          2025","DOI":"10.1155\/joot\/6424483"},{"key":"B25","unstructured":"Canadian Blood Services\n          \n          2025"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1097\/MOT.0b013e32834897c1","article-title":"Using donor exchange paradigms with desensitization to enhance transplant rates among highly sensitized patients","volume":"16","author":"Montgomery","year":"2011","journal-title":"Curr Opin Organ Transplant"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2005.01048.x","article-title":"Characterization of waiting times in a simulation of kidney paired donation","volume":"5","author":"Segev","year":"2005","journal-title":"Am J Transplant"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.14689","article-title":"Kidney exchange match rates in a large multicenter clearinghouse","volume":"18","author":"Holscher","year":"2018","journal-title":"Am J Transplant"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1177\/20543581211058932","article-title":"Compatible donor and recipient pairs\u2019 perspectives on participation in kidney paired donation programs: A mixed-methods study","volume":"8","author":"Fortin","year":"2021","journal-title":"Can J Kidney Health Dis"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0b013e318298f9db","article-title":"Relative importance of HLA mismatch and donor age to graft survival in young kidney transplant recipients","volume":"96","author":"Foster","year":"2013","journal-title":"Transplantation"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2020010019","article-title":"Eplet mismatch load and de novo occurrence of donor-specific anti-HLA antibodies, rejection, and graft failure after kidney transplantation: An observational cohort study","volume":"31","author":"Senev","year":"2020","journal-title":"J Am Soc Nephrol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.trim.2023.101908","article-title":"Impact of HLA eplet mismatch load in immunological outcomes after living donor kidney transplantation","volume":"80","author":"Alves","year":"2023","journal-title":"Transpl Immunol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0b013e3182802f88","article-title":"Efficacy, outcomes, and cost-effectiveness of desensitization using IVIG and rituximab","volume":"95","author":"Vo","year":"2013","journal-title":"Transplantation"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1012376","article-title":"Desensitization in HLA-incompatible kidney recipients and survival","volume":"365","author":"Montgomery","year":"2011","journal-title":"N Engl J Med"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1623684\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T05:23:13Z","timestamp":1772515393000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1623684\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,3]]},"references-count":34,"alternative-id":["10.3389\/fimmu.2026.1623684"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1623684","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,3]]},"article-number":"1623684"}}